Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis

Chronic Hand Dermatitis Clinical Trial

Official title:
A 6-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Pimecrolimus Cream 1% in Patients With Mild-to-Moderate Chronic Hand Dermatitis Followed by a 6-Week Open-Label Phase to Assess the Safety of Pimecrolimus Cream 1%

Status Completed

Clinical Trial Summary

Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00226707
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	July 2004
Completion date	March 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01482663` - Chronic Hand Eczema - Self-management and Prognosis	N/A
Completed	`NCT01545284` - Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis	Phase 2/Phase 3
Active, not recruiting	`NCT05293717` - Topical Ruxolitinib in Chronic Hand Dermatitis	Phase 1/Phase 2
Completed	`NCT03728504` - Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema	Phase 2
Withdrawn	`NCT03741933` - Apremilast and Moderate to Severe Chronic Hand Dermatitis	Phase 4
Completed	`NCT00556855` - Comparison Study With E-DO in Chronic Hand Dermatitis	N/A